Billionaire Profile
C
Global Rank
#550

Image: Linné, Carl von, 1707-1778 Devillers, Charles, 1724-1809 Crawford, J. C., former owner. DSI Buchanan, Lee LaForest, b. 1893, former owner. DSI Schaus, William, 1859- , former owner. DSI Aldrich, John Merton, 1866-1934, former owner. DSI Melander, A. L. (Axel Leonard), b. 1878, former owner. DSI U.S. Dept. of the Interior. Library, former owner. DSI | Public domain | via Wikimedia Commons

Cen Junda

CEO, Pharmaceuticals
CHINA
Real-Time Net Worth
$7.03B
Estimated based on Pharmaceuticals stock value as of March 6, 2026
+5.77% (24h)
Age
61
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
CHINA

Biography

Cen Junda is a prominent Chinese billionaire, recognized for his significant investments in the pharmaceutical industry. As of November 2025, he held a net worth of $8.55 billion, primarily stemming from his stake in Hansoh Pharmaceutical Group and his investments in Jiangsu Hengrui Pharmaceuticals. His strategic backing has been instrumental in the growth and success of these pharmaceutical companies. Cen Junda's financial acumen and investment decisions have contributed to his substantial wealth and his position among China's wealthiest individuals.

Fact Checked
Verified by Editorial Team
Live Data
Updated 3/6/2026

Wealth Over Time

In-Depth Profile

Early Life and Education

Details about Cen Junda's early life and education are limited in the available sources. However, it is known that he holds degrees from Zhejiang University and the China State Institute of Pharmaceutical Industry, which likely provided him with a strong foundation in the pharmaceutical sector.

Rise to Success

Cen Junda's rise to prominence is closely tied to his astute investment decisions within the pharmaceutical industry. He made significant investments in Hansoh Pharmaceutical Group and Jiangsu Hengrui Pharmaceuticals. These companies, under his backing, have become major players in the Chinese pharmaceutical market, contributing significantly to his wealth.

Key Business Strategies

Cen Junda's strategy appears to focus on identifying and investing in promising pharmaceutical companies with high growth potential. His investments in Hansoh Pharmaceutical Group and Jiangsu Hengrui Pharmaceuticals demonstrate his ability to recognize and support successful ventures. His investments in companies like Hansoh Pharmaceutical Group have enabled them to expand internationally, contributing to his financial success.

Philanthropy

Information regarding Cen Junda's philanthropic activities is not available in the provided search results.

Career Milestones

2019

Hansoh Pharmaceutical Group IPO

Cen Junda's investment in Hansoh Pharmaceutical Group contributed to its successful IPO on the Hong Kong Stock Exchange.